3月9日,CDE官网显示,康方生物自主研发的注射用AK150正式获批临床,适应症为晚期实体瘤。值得注意的是,AK150是康方生物首款获批临床的三特异性抗体产品,标志着公司在多特异性抗体领域的布局再下一城。AK150是一款靶向LILRB1、LILRB2和CSF1R的三特异性抗体,旨在调节肿瘤微环境中的巨噬细胞功能。根据公开信息,这是目前全球范围内唯一一款同时靶向LILRB1/LILRB2/CSF1R...
Source Link3月9日,CDE官网显示,康方生物自主研发的注射用AK150正式获批临床,适应症为晚期实体瘤。值得注意的是,AK150是康方生物首款获批临床的三特异性抗体产品,标志着公司在多特异性抗体领域的布局再下一城。AK150是一款靶向LILRB1、LILRB2和CSF1R的三特异性抗体,旨在调节肿瘤微环境中的巨噬细胞功能。根据公开信息,这是目前全球范围内唯一一款同时靶向LILRB1/LILRB2/CSF1R...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.